Adalimumab's promising potential in psoriasis REVEALed

    loading  Checking for direct PDF access through Ovid

Abstract

Adalimumab [Humira] is effective in both the short- and long-term treatment of patients with moderate to severe chronic plaque psoriasis, according to data from the phase III REVEAL* trial presented at the 65th Annual Meeting of the American Academy of Dermatology (AAD) [Washington, District of Columbia, US; February 2007]. The 52−week study showed that a significantly greater proportion of patients treated with adalimumab than placebo experienced a ≥ 75% improvement in their Psoriasis Area and Severity Index (PASI) score at week 16. Discontinuation of adalimumab therapy was associated with loss of adequate response; among adalimumab recipients re-randomised to placebo at week 33, a significant 28.4% lost adequate response by week 52, compared with 4.9% of patients re-randomised to continue treatment with adalimumab, demonstrating that most patients who responded to adalimumab and used it continuously were able to maintain their PASI response long-term.

Related Topics

    loading  Loading Related Articles